GSE115403
Inflammation-produced TNFa protects hematopoietic stem cells from necroptosis and promotes hematopoietic regeneration
To gain molecular insights into the differential effect of TNFa between hematopoietic stem cells (HSC) and downstream myeloid progenitors, we performed RNA-sequencing analyses of HSCs and granulocyte-macrophage progenitors (GMP) treated with TNFa both ex vivo and in vivo. Overall design: RNA sequencing of 3 biological replicates of HSCs (Lin-/cKit+/Sca1+/Flk2-/CD48-/CD150+) and GMPs (Lin-/cKit+/Sca1-/Fc?R+/CD34+) treated ± TNFa both ex vivo for 3 and 12 hours and in vivo for 3 hour (1x3hr). For ex vivo treatment of TNFa, HSCs and GMPs were isolated by FACS from C57BL/6 mouse bone marrow (BM) and cultured in liquid media ± TNFa for either 3 or 12 hours. For in vivo treatment, HSCs and GMPs were isolated from C57BL/6 mice 3 hours after a single injection of PBS or TNFa.